A phase 3 clinical trial in which the molecular profiling of advanced sarcoma will guide the choice of the appropriate targeted therapy is recruiting (NCT03784014): a patient with sarcoma presenting EGFR or HER2 molecular drivers will be treated with the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib. The gene discussed is ERBB2; the disease is sarcoma.